Galvanize Therapeutics is a medical device company at the forefront of developing pulsed electric field (PEF) energy devices. Their core mission is to harness the body's inherent biological responses to combat disease and reinstate normal physiological function. The company's flagship products, the Aliya® PEF System and the Aliya® EX System, are 510(k) cleared in the United States for the surgical ablation of soft tissue. These systems are engineered to deliver precise energy application to target lesions, offering clinicians flexibility through adjustable ablation energy settings.

The Aliya PEF technology operates by creating a predictable cellular depletion zone, which has demonstrated a favourable safety profile, even when used near sensitive anatomical structures. A key differentiator of their technology is its potential for immune activation, suggesting broader therapeutic benefits beyond mere tissue destruction. The systems are designed for seamless integration into existing clinical workflows, tools, and standard of care, ensuring ease of adoption for healthcare providers. Galvanize Therapeutics also offers the RheOx® System, though specific details on its application are less prominent on the provided page.

The company's devices are primarily intended for healthcare providers, including surgeons and interventional radiologists, who perform soft tissue ablation procedures. The technology aims to improve patient outcomes by offering a precise, safe, and potentially immunogenic approach to tissue removal. While the Aliya PEF System is cleared for surgical ablation of soft tissue, Galvanize Therapeutics explicitly states that it does not promote off-label use and that the system is not intended to treat, cure, prevent, or mitigate any specific disease or condition, but rather serves as a tool for surgical ablation.

Galvanize Therapeutics has seen significant adoption, with over 100 Aliya PEF ablation procedures completed and more than 10 physicians using the system across multiple hospitals as of August 2026. This indicates a growing acceptance and clinical utility of their technology within the medical community. The company's commitment to innovation is further evidenced by its recent Series D financing, aimed at accelerating commercial growth, and ongoing clinical evidence suggesting the immune-activating potential of its PEF energy.